2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
… simulations to support go/no-go decisions, trial design optimization, and regulatory interactions. Skills and … As an employer, we value a diverse workforce in which people are encouraged to develop themselves both personally and professionally. We …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… Pharmacodynamic modelling expert to join our Translational Development Team. The Translational Development Team works in … activities include: Prepare mechanistic minimal PBPK and/ (population) PKPD M&S-based strategies to support discovery … generate predictive (human) exposure profiles and to guide optimal dosing strategies and ensure therapeutic efficacy and …
… approaches to drive scientific and operational excellence. Develop and determine optimal methods for new assignments by … As an employer, we value a diverse workforce in which people are encouraged to develop themselves both personally … 30 vacation days An annual performance bonus Stock options A premium-free pension plan A commuting allowance A …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
